Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease

J. E. Gadek, J. D. Fulmer, J. A. Gelfand, M. M. Frank, T. L. Petty, Ronald Crystal

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

Individuals with serum α1-antitrypsin levels below 80 mg/dl are clearly at risk for the development of accelerated panacinar emphysema. One possible approach to the therapy of this disorder would be to raise serum levels of this major antiprotease to establish protease-antiprotease homeostasis within the lung parenchyma. Because danazol, an impeded androgen, elevates levels of C1 inhibitor in patients deficient of that serum antiprotease, the authors hypothesized that this agent might also increase α1-antitrypsin levels in patients with α1-antitrypsin deficiency. To evaluate this concept, seven patients with severe emphysema associated with α1-antitrypsin deficiency [six PiZ and 1 M(Duarte)Z] and one asymptomatic individual (PiSZ) received 600 mg of danazol daily for 30 days. Five of the six PiZ patients responded to danazol therapy with significant increases in serum α1-antitrypsin levels (mean increase of 37%; P < 0.03). The two individuals who were heterozygous for the Z protein increased their serum levels by 85% [PiM(Duarte)Z] and 87% (PiSZ), respectively. These increases in serum α1-antitrypsin antigen were accompanied by commensurate increases in serum trypsin inhibition. Crossed immunoelectrophoresis showed no alterations of the microheterogeneity of the α1-antitrypsin or the presence of protease-antiprotease complexes in serum during danazol therapy. These data demonstrate that serum α1-antitrypsin levels can be augmented by danazol therapy in PiZ individuals as well as those heterozygotes with severe deficiency of α1-antitrypsin. The clinical relevance of these increases in serum α1-antitrypsin remains speculative, but these findings suggest that danazol may provide a means of improving the protease-antiprotease balance in these individuals and thus impede the progression of their lung disease.

Original languageEnglish
Pages (from-to)82-87
Number of pages6
JournalJournal of Clinical Investigation
Volume66
Issue number1
DOIs
Publication statusPublished - 1 Jan 1980
Externally publishedYes

Fingerprint

Danazol
Protease Inhibitors
Serum
Peptide Hydrolases
Two-Dimensional Immunoelectrophoresis
Pulmonary Emphysema
Emphysema
Therapeutics
Heterozygote
Trypsin
Androgens
Lung Diseases
Homeostasis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease. / Gadek, J. E.; Fulmer, J. D.; Gelfand, J. A.; Frank, M. M.; Petty, T. L.; Crystal, Ronald.

In: Journal of Clinical Investigation, Vol. 66, No. 1, 01.01.1980, p. 82-87.

Research output: Contribution to journalArticle

Gadek, J. E. ; Fulmer, J. D. ; Gelfand, J. A. ; Frank, M. M. ; Petty, T. L. ; Crystal, Ronald. / Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease. In: Journal of Clinical Investigation. 1980 ; Vol. 66, No. 1. pp. 82-87.
@article{3d68cfc6444c4959a9fab8ca902e901f,
title = "Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease",
abstract = "Individuals with serum α1-antitrypsin levels below 80 mg/dl are clearly at risk for the development of accelerated panacinar emphysema. One possible approach to the therapy of this disorder would be to raise serum levels of this major antiprotease to establish protease-antiprotease homeostasis within the lung parenchyma. Because danazol, an impeded androgen, elevates levels of C1 inhibitor in patients deficient of that serum antiprotease, the authors hypothesized that this agent might also increase α1-antitrypsin levels in patients with α1-antitrypsin deficiency. To evaluate this concept, seven patients with severe emphysema associated with α1-antitrypsin deficiency [six PiZ and 1 M(Duarte)Z] and one asymptomatic individual (PiSZ) received 600 mg of danazol daily for 30 days. Five of the six PiZ patients responded to danazol therapy with significant increases in serum α1-antitrypsin levels (mean increase of 37{\%}; P < 0.03). The two individuals who were heterozygous for the Z protein increased their serum levels by 85{\%} [PiM(Duarte)Z] and 87{\%} (PiSZ), respectively. These increases in serum α1-antitrypsin antigen were accompanied by commensurate increases in serum trypsin inhibition. Crossed immunoelectrophoresis showed no alterations of the microheterogeneity of the α1-antitrypsin or the presence of protease-antiprotease complexes in serum during danazol therapy. These data demonstrate that serum α1-antitrypsin levels can be augmented by danazol therapy in PiZ individuals as well as those heterozygotes with severe deficiency of α1-antitrypsin. The clinical relevance of these increases in serum α1-antitrypsin remains speculative, but these findings suggest that danazol may provide a means of improving the protease-antiprotease balance in these individuals and thus impede the progression of their lung disease.",
author = "Gadek, {J. E.} and Fulmer, {J. D.} and Gelfand, {J. A.} and Frank, {M. M.} and Petty, {T. L.} and Ronald Crystal",
year = "1980",
month = "1",
day = "1",
doi = "10.1172/JCI109838",
language = "English",
volume = "66",
pages = "82--87",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - Danazol-induced augmentation of serum α1-antitrypsin levels in individuals with marked deficiency of this antiprotease

AU - Gadek, J. E.

AU - Fulmer, J. D.

AU - Gelfand, J. A.

AU - Frank, M. M.

AU - Petty, T. L.

AU - Crystal, Ronald

PY - 1980/1/1

Y1 - 1980/1/1

N2 - Individuals with serum α1-antitrypsin levels below 80 mg/dl are clearly at risk for the development of accelerated panacinar emphysema. One possible approach to the therapy of this disorder would be to raise serum levels of this major antiprotease to establish protease-antiprotease homeostasis within the lung parenchyma. Because danazol, an impeded androgen, elevates levels of C1 inhibitor in patients deficient of that serum antiprotease, the authors hypothesized that this agent might also increase α1-antitrypsin levels in patients with α1-antitrypsin deficiency. To evaluate this concept, seven patients with severe emphysema associated with α1-antitrypsin deficiency [six PiZ and 1 M(Duarte)Z] and one asymptomatic individual (PiSZ) received 600 mg of danazol daily for 30 days. Five of the six PiZ patients responded to danazol therapy with significant increases in serum α1-antitrypsin levels (mean increase of 37%; P < 0.03). The two individuals who were heterozygous for the Z protein increased their serum levels by 85% [PiM(Duarte)Z] and 87% (PiSZ), respectively. These increases in serum α1-antitrypsin antigen were accompanied by commensurate increases in serum trypsin inhibition. Crossed immunoelectrophoresis showed no alterations of the microheterogeneity of the α1-antitrypsin or the presence of protease-antiprotease complexes in serum during danazol therapy. These data demonstrate that serum α1-antitrypsin levels can be augmented by danazol therapy in PiZ individuals as well as those heterozygotes with severe deficiency of α1-antitrypsin. The clinical relevance of these increases in serum α1-antitrypsin remains speculative, but these findings suggest that danazol may provide a means of improving the protease-antiprotease balance in these individuals and thus impede the progression of their lung disease.

AB - Individuals with serum α1-antitrypsin levels below 80 mg/dl are clearly at risk for the development of accelerated panacinar emphysema. One possible approach to the therapy of this disorder would be to raise serum levels of this major antiprotease to establish protease-antiprotease homeostasis within the lung parenchyma. Because danazol, an impeded androgen, elevates levels of C1 inhibitor in patients deficient of that serum antiprotease, the authors hypothesized that this agent might also increase α1-antitrypsin levels in patients with α1-antitrypsin deficiency. To evaluate this concept, seven patients with severe emphysema associated with α1-antitrypsin deficiency [six PiZ and 1 M(Duarte)Z] and one asymptomatic individual (PiSZ) received 600 mg of danazol daily for 30 days. Five of the six PiZ patients responded to danazol therapy with significant increases in serum α1-antitrypsin levels (mean increase of 37%; P < 0.03). The two individuals who were heterozygous for the Z protein increased their serum levels by 85% [PiM(Duarte)Z] and 87% (PiSZ), respectively. These increases in serum α1-antitrypsin antigen were accompanied by commensurate increases in serum trypsin inhibition. Crossed immunoelectrophoresis showed no alterations of the microheterogeneity of the α1-antitrypsin or the presence of protease-antiprotease complexes in serum during danazol therapy. These data demonstrate that serum α1-antitrypsin levels can be augmented by danazol therapy in PiZ individuals as well as those heterozygotes with severe deficiency of α1-antitrypsin. The clinical relevance of these increases in serum α1-antitrypsin remains speculative, but these findings suggest that danazol may provide a means of improving the protease-antiprotease balance in these individuals and thus impede the progression of their lung disease.

UR - http://www.scopus.com/inward/record.url?scp=0018875422&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018875422&partnerID=8YFLogxK

U2 - 10.1172/JCI109838

DO - 10.1172/JCI109838

M3 - Article

C2 - 6967489

AN - SCOPUS:0018875422

VL - 66

SP - 82

EP - 87

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -